H.R. 8339

119th CongressIn committee

Drug Origin Transparency Act of 2026

Drug Origin Transparency Act of 2026

Sponsored by Doris O. Matsui (Democrat-CA-7)

Healthcare Costs & Access Healthcare & Public Health Pharmaceutical Policy

Cosponsors

3

Actions

3

Roll calls

0

Amendments

0

Related bills

0

Actions

Apr 16, 2026 · Library of Congress

Introduced in House

Apr 16, 2026 · Library of Congress

Introduced in House

Apr 16, 2026 · House floor actions

Referred to the House Committee on Energy and Commerce.

Latest activity

Activity

July 2026

Lobbying reported · Association for Accessible Medicines · Jul 20

Association for Accessible Medicines reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Accessible Medicines — $870,000

BillsH.R. 3160 H.R. 3269 H.R. 5526 H.R. 5811 H.R. 6485 H.R. 7148 H.R. 8269 H.R. 8339 S. 43 S. 1096 S. 1414 S. 1546 S. 1553 S. 1954 S. 2658 S. 3469 S. 3788

Lobbying reported · Vizient · Jul 20

Vizient reported 2nd Quarter (Apr 1 - June 30) lobbying for Vizient — $320,000

BillsH.R. 2213 H.R. 3178 H.R. 3514 H.R. 3890 H.R. 4191 H.R. 4731 H.R. 8339 S. 1784 S. 1816 S. 1954 S. 2556

Lobbying reported · Association for Clinical Oncology (ASCO) · Jul 16

Association for Clinical Oncology (ASCO) reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Clinical Oncology (ASCO) — $480,000

You’re all caught up.